Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hydroxychloroquine reduces IL-6 and pro-thrombotic status

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. The study of interactions between genome and exposome in the development of systemic lupus erythematosus

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pattern recognition receptor polymorphisms in early periodontitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Caterina Bodio
  • Claudia Grossi
  • Francesca Pregnolato
  • Ennio Giulio Favalli
  • Martina Biggioggero
  • Antonio Marchesoni
  • Antonella Murgo
  • Matteo Filippini
  • Paola Migliorini
  • Roberto Caporali
  • Raffaele Pellerito
  • Francesco Ciccia
  • Piercarlo Sarzi-Puttini
  • Federico Perosa
  • Giuseppe Paolazzi
  • Ivana Hollan
  • Klaus Bendtzen
  • Pier Luigi Meroni
  • Maria Orietta Borghi
Vis graf over relationer

Up to 40% of patients treated with tumor necrosis factor alpha inhibitors (TNFi) do not respond to therapy. Testing drug bioavailability and/or anti-drug antibody (ADAb) levels may justify dosage adjustment or switch to different drugs, enabling a personalized medicine approach. We report a multicenter cross-sectional study on different methods [ELISA and a cell based functional assay (reporter gene assay - RGA)] for drug/ADAb detection, and on the relationship between drug bioavailability and ADAb. 163 patients with rheumatoid arthritis (RA) treated with infliximab (IFX; n = 67), adalimumab (ADL; n = 49) or etanercept (ETA; n = 47) were tested for drug and ADAb levels. Furthermore, we report prospective data from additional 70 patients (59 RA and 11 juvenile idiopathic arthritis - JIA) tested for drug and ADAb levels at baseline (T0) and after 3 (T3) and 6 months (T6) of treatment with ADL or ETA only. IFX-treated patients were not included because of the increasing use of IFX biosimilars. Stringent inclusion criteria were used in order to avoid unwanted variables in both studies; none of the patients used TNFi before the study, and TNFi was used only in combination with methotrexate. Clinical response was defined according to EULAR response criteria. The two assays performed comparably in the comparison study. Accordingly, ELISA was selected for the prospective study because of its feasibility in the clinical setting. The cross-sectional study found ADAb in IFX and ADL treated groups only, that were associated with a decrease in pharmacological drug availability in the blood. Comparable results were found for the ADL-treated group in the prospective study which also showed a relationship between drug/ADAb levels and the loss of clinical response. Altogether our findings support drug and anti-drug Ab monitoring in the real-world clinical setting thus enabling individualized treatment and reducing disability in chronic inflammatory arthritis.

OriginalsprogEngelsk
TidsskriftAutoimmunity Reviews
Vol/bind19
Udgave nummer5
Sider (fra-til)102509
ISSN1568-9972
DOI
StatusUdgivet - maj 2020

Bibliografisk note

Copyright © 2020 Elsevier B.V. All rights reserved.

ID: 61865294